Target family: Inwardly rectifying potassium channels (K<sub>IR</sub>) (type: vgic)
Target: K<sub>ir</sub>1.1

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Cloning and expression of an inwardly rectifying ATP-regulated potassium channel.
Published in: Nature

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Mutations in the pore region of ROMK enhance Ba2+ block.
Published in: Am J Physiol

Ligand: Ba2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Cloning and characterization of multiple forms of the human kidney ROM-K potassium channel.
Published in: J Biol Chem

Ligand: Cs+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 2.9000000953674316 pIC50
Reference (Journal): Mutations in the pore region of ROMK enhance Ba2+ block.
Published in: Am J Physiol

Ligand: H+ (Inorganic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Intracellular H+ inhibits a cloned rat kidney outer medulla K+ channel expressed in Xenopus oocytes.
Published in: Am J Physiol

Ligand: H+ (Inorganic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Permeant cations and blockers modulate pH gating of ROMK channels.
Published in: Biophys J

Ligand: H+ (Inorganic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels.
Published in: J Biol Chem

Ligand: K+ (Inorganic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 2.299999952316284 pEC50
Reference (Journal): Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels.
Published in: J Biol Chem

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 2.299999952316284 pKi
Reference (Journal): Mg(2+)-dependent inward rectification of ROMK1 potassium channels expressed in Xenopus oocytes.
Published in: J Physiol (Lond.)

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 2.200000047683716 pKi
Reference (Journal): Magnesium modulates ROMK channel-mediated potassium secretion.
Published in: J Am Soc Nephrol

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 2.299999952316284 pKi
Reference (Journal): Magnesium modulates ROMK channel-mediated potassium secretion.
Published in: J Am Soc Nephrol

Ligand: MK-7145 (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.
Published in: ACS Med Chem Lett

Ligand: MK-8153 (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic.
Published in: J Med Chem

Ligand: [125I]tertiapin Y1/K12/Q13 (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): Characterization of Kir1.1 channels with the use of a radiolabeled derivative of tertiapin.
Published in: Biochemistry

Ligand: tertiapin-Q (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of Kir1.1 channels with the use of a radiolabeled derivative of tertiapin.
Published in: Biochemistry

Ligand: tertiapin-Q (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): Synthesis of a stable form of tertiapin: a high-affinity inhibitor for inward-rectifier K+ channels.
Published in: Biochemistry

Ligand: tertiapin-Q (Peptide)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.899999618530273 pIC50
Reference (Journal): Synthesis of a stable form of tertiapin: a high-affinity inhibitor for inward-rectifier K+ channels.
Published in: Biochemistry

Ligand: tertiapin-Q (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Synthesis of a stable form of tertiapin: a high-affinity inhibitor for inward-rectifier K+ channels.
Published in: Biochemistry

Ligand: VU591 (Synthetic organic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.599999904632568 pKi
Reference (Journal): Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel.
Published in: Mol Pharmacol